Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

GlobalNewswire
27 April 2022
https://www.globenewswire.com/news-release/2022/04/27/2430707/0/en/Statera-Biopharma-and-Immune-Therapeutics-Inc-Announce-Strategic-Agreement-for-Rights-to-Low-Dose-Naltrexone.html

Find out if you qualify for these clinical trials enrolling now

Senior Matters
03 April 2022https://www.seniorsmatter.com/find-out-if-you-qualify-for-these-clinical-trials-enrolling-now/2602035/

One  of the studies will evaluate the short-, intermediate and long-term effects of low-dose naltrexone on quality of life and age-associated diseases